Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact

Figure 1 mean ± SD change from baseline in laboratory parameters in inflammatory bowel disease patients with iron deficiency/iron deficiency anaemia treated with a single 1000 mg intravenous dose of ferric carboxymaltose or ferric derisomaltose. A: Fractional excretion of phosphate; B: Intact fibroblast growth factor 23; C: C-terminal fibroblast growth factor 23; D: 25-Hydroxyvitamin D; E: 1,25-Hydroxyvitamin D; F: Ionised calcium; G: Parathyroid hormone. FCM: Ferric carboxymaltose; FDI: Ferric derisomaltose; FEPO₄: Fractional excretion of phosphate; FGF23: Fibroblast growth factor 23; PTH: Parathyroid hormone.